Nexalin Technology (NXL) Competitors

$0.32 0.00 (-1.08%)

Closing price 05/19/2026 04:00 PM Eastern

Extended Trading

$0.31 -0.01 (-4.36%)

As of 05/19/2026 07:53 PM Eastern

NXL vs. PETV, FEMY, POAI, RVP, and ICCM

Should you buy Nexalin Technology stock or one of its competitors? MarketBeat compares Nexalin Technology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nexalin Technology include PetVivo (PETV), Femasys (FEMY), Predictive Oncology (POAI), Retractable Technologies (RVP), and IceCure Medical (ICCM). These companies are all part of the "medical equipment" industry.

How does Nexalin Technology compare to PetVivo?

Nexalin Technology (NASDAQ:NXL) and PetVivo (NASDAQ:PETV) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Nexalin Technology had 1 more articles in the media than PetVivo. MarketBeat recorded 2 mentions for Nexalin Technology and 1 mentions for PetVivo. PetVivo's average media sentiment score of 0.67 beat Nexalin Technology's score of 0.00 indicating that PetVivo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nexalin Technology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PetVivo	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nexalin Technology has higher earnings, but lower revenue than PetVivo. PetVivo is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	22.02	-$8.22M	-$0.47	N/A
PetVivo	$1.05M	27.57	-$10.95M	-$0.38	N/A

PetVivo has a net margin of -902.82% compared to Nexalin Technology's net margin of -3,018.12%. Nexalin Technology's return on equity of -191.88% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,018.12%	-191.88%	-166.43%
PetVivo	-902.82%	-4,813.07%	-281.78%

0.7% of Nexalin Technology shares are owned by institutional investors. Comparatively, 24.5% of PetVivo shares are owned by institutional investors. 25.3% of Nexalin Technology shares are owned by company insiders. Comparatively, 10.8% of PetVivo shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Nexalin Technology has a beta of 3.56, indicating that its stock price is 256% more volatile than the broader market. Comparatively, PetVivo has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market.

Summary

Nexalin Technology beats PetVivo on 8 of the 14 factors compared between the two stocks.

How does Nexalin Technology compare to Femasys?

Nexalin Technology (NASDAQ:NXL) and Femasys (NASDAQ:FEMY) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

0.7% of Nexalin Technology shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 25.3% of Nexalin Technology shares are held by insiders. Comparatively, 7.6% of Femasys shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Nexalin Technology has higher earnings, but lower revenue than Femasys. Femasys is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	22.02	-$8.22M	-$0.47	N/A
Femasys	$2.29M	9.46	-$18.63M	-$0.27	N/A

In the previous week, Femasys had 2 more articles in the media than Nexalin Technology. MarketBeat recorded 4 mentions for Femasys and 2 mentions for Nexalin Technology. Nexalin Technology's average media sentiment score of 0.00 equaled Femasys'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nexalin Technology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Femasys has a net margin of -521.97% compared to Nexalin Technology's net margin of -3,018.12%. Nexalin Technology's return on equity of -191.88% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,018.12%	-191.88%	-166.43%
Femasys	-521.97%	-258.08%	-73.72%

Femasys has a consensus price target of $5.33, suggesting a potential upside of 1,387.27%. Given Femasys' stronger consensus rating and higher possible upside, analysts clearly believe Femasys is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nexalin Technology has a beta of 3.56, indicating that its share price is 256% more volatile than the broader market. Comparatively, Femasys has a beta of -2.26, indicating that its share price is 326% less volatile than the broader market.

Summary

Femasys beats Nexalin Technology on 9 of the 15 factors compared between the two stocks.

How does Nexalin Technology compare to Predictive Oncology?

Predictive Oncology (NASDAQ:POAI) and Nexalin Technology (NASDAQ:NXL) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by company insiders. Comparatively, 25.3% of Nexalin Technology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Nexalin Technology had 1 more articles in the media than Predictive Oncology. MarketBeat recorded 2 mentions for Nexalin Technology and 1 mentions for Predictive Oncology. Predictive Oncology's average media sentiment score of 0.75 beat Nexalin Technology's score of 0.00 indicating that Predictive Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Predictive Oncology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nexalin Technology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nexalin Technology has lower revenue, but higher earnings than Predictive Oncology. Nexalin Technology is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.66M	9.54	-$12.66M	-$13.50	N/A
Nexalin Technology	$300K	22.02	-$8.22M	-$0.47	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nexalin Technology has a net margin of -3,018.12% compared to Predictive Oncology's net margin of -5,065.23%. Nexalin Technology's return on equity of -191.88% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	-732.73%	-235.55%
Nexalin Technology	-3,018.12%	-191.88%	-166.43%

Predictive Oncology has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market. Comparatively, Nexalin Technology has a beta of 3.56, indicating that its share price is 256% more volatile than the broader market.

Summary

Nexalin Technology beats Predictive Oncology on 9 of the 13 factors compared between the two stocks.

How does Nexalin Technology compare to Retractable Technologies?

Retractable Technologies (NYSE:RVP) and Nexalin Technology (NASDAQ:NXL) are both small-cap medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Retractable Technologies has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market. Comparatively, Nexalin Technology has a beta of 3.56, meaning that its stock price is 256% more volatile than the broader market.

In the previous week, Retractable Technologies and Retractable Technologies both had 2 articles in the media. Retractable Technologies' average media sentiment score of 0.00 equaled Nexalin Technology'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Retractable Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nexalin Technology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Retractable Technologies has higher revenue and earnings than Nexalin Technology. Retractable Technologies is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Retractable Technologies	$38.27M	0.53	-$7.01M	-$0.21	N/A
Nexalin Technology	$300K	22.02	-$8.22M	-$0.47	N/A

Retractable Technologies has a net margin of -41.11% compared to Nexalin Technology's net margin of -3,018.12%. Retractable Technologies' return on equity of -17.15% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Retractable Technologies	-41.11%	-17.15%	-9.33%
Nexalin Technology	-3,018.12%	-191.88%	-166.43%

7.6% of Retractable Technologies shares are held by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are held by institutional investors. 59.5% of Retractable Technologies shares are held by insiders. Comparatively, 25.3% of Nexalin Technology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Retractable Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Retractable Technologies beats Nexalin Technology on 8 of the 12 factors compared between the two stocks.

How does Nexalin Technology compare to IceCure Medical?

Nexalin Technology (NASDAQ:NXL) and IceCure Medical (NASDAQ:ICCM) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

IceCure Medical has a net margin of -441.60% compared to Nexalin Technology's net margin of -3,018.12%. Nexalin Technology's return on equity of -191.88% beat IceCure Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,018.12%	-191.88%	-166.43%
IceCure Medical	-441.60%	-211.73%	-119.13%

IceCure Medical has a consensus target price of $2.09, suggesting a potential upside of 816.67%. Given IceCure Medical's stronger consensus rating and higher probable upside, analysts plainly believe IceCure Medical is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IceCure Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Nexalin Technology has higher earnings, but lower revenue than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300K	22.02	-$8.22M	-$0.47	N/A
IceCure Medical	$3.38M	5.48	-$15.06M	-$0.24	N/A

Nexalin Technology has a beta of 3.56, meaning that its share price is 256% more volatile than the broader market. Comparatively, IceCure Medical has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market.

In the previous week, IceCure Medical had 11 more articles in the media than Nexalin Technology. MarketBeat recorded 13 mentions for IceCure Medical and 2 mentions for Nexalin Technology. Nexalin Technology's average media sentiment score of 0.00 beat IceCure Medical's score of -0.56 indicating that Nexalin Technology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nexalin Technology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IceCure Medical	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

0.7% of Nexalin Technology shares are held by institutional investors. Comparatively, 0.6% of IceCure Medical shares are held by institutional investors. 25.3% of Nexalin Technology shares are held by insiders. Comparatively, 2.4% of IceCure Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Nexalin Technology and IceCure Medical tied by winning 8 of the 16 factors compared between the two stocks.

Get Nexalin Technology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NXL vs. The Competition

Export

Metric	Nexalin Technology	Technology Services Industry	Business Sector	NASDAQ Exchange
Market Cap	$6.68M	$3.70B	$6.49B	$12.23B
Dividend Yield	N/A	2.21%	3.15%	5.32%
P/E Ratio	-0.68	46.95	29.17	25.05
Price / Sales	22.02	48.82	399.47	72.68
Price / Cash	N/A	38.11	22.70	54.25
Price / Book	2.29	5.20	6.75	6.83
Net Income	-$8.22M	$31.26M	$204.94M	$335.69M
7 Day Performance	-5.70%	-3.62%	-1.52%	-2.15%
1 Month Performance	-31.15%	-7.37%	-5.27%	-2.47%
1 Year Performance	-73.90%	24.88%	28.34%	27.13%

Nexalin Technology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NXL Nexalin Technology	0.2249 of 5 stars	$0.32 -1.1%	N/A	-74.7%	$6.68M	$300K	N/A	3	News Coverage Positive News Gap Down High Trading Volume
PETV PetVivo	N/A	$0.75 -6.1%	N/A	+14.1%	$26.89M	$1.05M	N/A	20	News Coverage
FEMY Femasys	2.0519 of 5 stars	$0.38 -6.7%	$5.33 +1,314.3%	-65.5%	$24.41M	$2.38M	N/A	30	News Coverage Analyst Downgrade
POAI Predictive Oncology	0.1957 of 5 stars	$6.66 +17.5%	N/A	-68.8%	$22.60M	$1.66M	N/A	30
RVP Retractable Technologies	N/A	$0.70 +2.4%	N/A	-9.2%	$20.96M	$38.27M	N/A	240

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NXL) was last updated on 5/20/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nexalin Technology (NXL) Competitors

NXL vs. PETV, FEMY, POAI, RVP, and ICCM

How does Nexalin Technology compare to PetVivo?

Summary

How does Nexalin Technology compare to Femasys?

Summary

How does Nexalin Technology compare to Predictive Oncology?

Summary

How does Nexalin Technology compare to Retractable Technologies?

Summary

How does Nexalin Technology compare to IceCure Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXL vs. The Competition

Nexalin Technology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nexalin Technology (NXL) Competitors

NXL vs. PETV, FEMY, POAI, RVP, and ICCM

How does Nexalin Technology compare to PetVivo?

Do analysts rate NXL or PETV?

Does the media refer more to NXL or PETV?

Which has higher earnings & valuation, NXL or PETV?

Is NXL or PETV more profitable?

Do insiders and institutionals have more ownership in NXL or PETV?

Which has more volatility & risk, NXL or PETV?

Summary

How does Nexalin Technology compare to Femasys?

Do insiders & institutionals have more ownership in NXL or FEMY?

Which has preferable valuation & earnings, NXL or FEMY?

Does the media refer more to NXL or FEMY?

Is NXL or FEMY more profitable?

Do analysts recommend NXL or FEMY?

Which has more risk and volatility, NXL or FEMY?

Summary

How does Nexalin Technology compare to Predictive Oncology?

Do institutionals and insiders hold more shares of POAI or NXL?

Does the media prefer POAI or NXL?

Which has better valuation & earnings, POAI or NXL?

Do analysts prefer POAI or NXL?

Is POAI or NXL more profitable?

Which has more risk and volatility, POAI or NXL?

Summary

How does Nexalin Technology compare to Retractable Technologies?

Which has more risk & volatility, RVP or NXL?

Does the media prefer RVP or NXL?

Which has better valuation and earnings, RVP or NXL?

Is RVP or NXL more profitable?

Do institutionals and insiders believe in RVP or NXL?

Do analysts rate RVP or NXL?

Summary

How does Nexalin Technology compare to IceCure Medical?

Is NXL or ICCM more profitable?

Do analysts recommend NXL or ICCM?

Which has higher earnings and valuation, NXL or ICCM?

Which has more risk and volatility, NXL or ICCM?

Does the media favor NXL or ICCM?

Do insiders & institutionals have more ownership in NXL or ICCM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXL vs. The Competition

Nexalin Technology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools